438 related articles for article (PubMed ID: 33930048)
41. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
[TBL] [Abstract][Full Text] [Related]
42. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
[TBL] [Abstract][Full Text] [Related]
43. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
Cagnotto G; Willim M; Nilsson JÅ; Compagno M; Jacobsson LTH; Saevarsdottir S; Turesson C
Arthritis Res Ther; 2020 Jan; 22(1):15. PubMed ID: 31969172
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
45. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
46. Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
Harrold LR; Connolly SE; Wittstock K; Zhuo J; Kelly S; Lehman T; Shan Y; Rebello S; Guo L; Khaychuk V
Rheumatol Ther; 2022 Apr; 9(2):465-480. PubMed ID: 34940957
[TBL] [Abstract][Full Text] [Related]
47. Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry.
Kim SK; Kwak SG; Choe JY
Medicine (Baltimore); 2020 Feb; 99(9):e19415. PubMed ID: 32118795
[TBL] [Abstract][Full Text] [Related]
48. Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis.
Klink AJ; Curtice TG; Gupta K; Tuell KW; Szymialis AR; Nero D; Feinberg BA
Am J Manag Care; 2019 Oct; 25(10):e288-e295. PubMed ID: 31622068
[TBL] [Abstract][Full Text] [Related]
49. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
Kida D; Takahashi N; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Ando M; Kuwatsuka Y; Tanaka E; Yasuoka H; Kaneko Y; Hirata S; Murakami K; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
Sci Rep; 2020 Nov; 10(1):19717. PubMed ID: 33184461
[TBL] [Abstract][Full Text] [Related]
50. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
51. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
Suissa S; Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P
Semin Arthritis Rheum; 2019 Dec; 49(3):366-372. PubMed ID: 30979397
[TBL] [Abstract][Full Text] [Related]
52. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
53. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
54. Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea.
Park JA; Lee MY; Nam JH; Shin JY; Wood R; Holbrook T; Kwon SH
Curr Med Res Opin; 2020 Feb; 36(2):343-351. PubMed ID: 31670976
[No Abstract] [Full Text] [Related]
55. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
[TBL] [Abstract][Full Text] [Related]
56. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
Schäfer M; Meißner Y; Kekow J; Berger S; Remstedt S; Manger B; Listing J; Strangfeld A; Zink A
Rheumatology (Oxford); 2020 Aug; 59(8):1916-1926. PubMed ID: 31745566
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis.
Iannone F; Lopalco G; Cacciapaglia F; Venerito V; Perniola S; Fornaro M
Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37991871
[TBL] [Abstract][Full Text] [Related]
58. Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis.
Rosenberg V; Chodick G; Xue Z; Faccin F; Amital H
Adv Ther; 2023 Oct; 40(10):4504-4522. PubMed ID: 37566157
[TBL] [Abstract][Full Text] [Related]
59. Factors that influence biological survival in rheumatoid arthritis: results of a real-world academic cohort from the Netherlands.
van Mulligen E; Ahmed S; Weel AEAM; Hazes JMW; van der Helm-van Mil AHM; de Jong PHP
Clin Rheumatol; 2021 Jun; 40(6):2177-2183. PubMed ID: 33415451
[TBL] [Abstract][Full Text] [Related]
60. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
